Literature DB >> 3019502

Rates of death from testicular cancer in Ontario in 1964-82: analysis by major histologic subgroups.

L D Marrett, H K Weir, E A Clarke, C J Magee.   

Abstract

In 1977 the rate of death from testicular cancer in Ontario began to decline following a long period of relative stability. This coincided with the addition of cisplatin to the chemotherapeutic regimens used in the treatment of disseminated germ-cell testicular cancer. A study was carried out to determine whether the decline has been similar for the two major histologic subgroups, seminoma and nonseminoma. By means of Ontario Cancer Registry data, histologic type was determined for all testicular cancers causing death in Ontario residents between 1964 and 1982, and death rates were calculated for seminoma and nonseminoma germ-cell testicular cancer. The rates of death from nonseminoma exceeded those from seminoma for the entire study period. Although the death rates for both subgroups declined by about 50% after 1976, the reduction in the overall rate of death from testicular cancer is primarily attributable to the decline in the rate for nonseminoma germ-cell testicular cancer. The increased overall rate of death from testicular cancer (all types) between 1980 and 1984 is cause for concern and indicates the need for continued monitoring of the trends in rates of death from this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019502      PMCID: PMC1491278     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  5 in total

1.  Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer.

Authors:  P H Lange; K R McIntire; T A Waldmann; T R Hakala; E E Fraley
Journal:  N Engl J Med       Date:  1976-11-25       Impact factor: 91.245

2.  Testicular tumors of germ cell origin.

Authors:  J H Kaplan; H G Kudish; S A Sacks
Journal:  Postgrad Med       Date:  1981-12       Impact factor: 3.840

3.  Improved survival rates among testis cancer patients in the United States.

Authors:  F P Li; R R Connelly; M Myers
Journal:  JAMA       Date:  1982-02-12       Impact factor: 56.272

4.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

5.  The increasing incidence of testicular cancer in East Anglia.

Authors:  A B Nethersell; L K Drake; K Sikora
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.